Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK), dated March 30, 2020, announces a revision to the reporting format for its Consumer Healthcare segment. The change follows the July 31, 2019, closing of the joint venture with Pfizer. The new disclosure structure replaces previous "Nutrition" and "Skin health" categories with five specific categories aligned with global power brands and industry standards. This revised format applies to Q1 2020 results and has been retroactively applied to 2019 and 2018 comparative data.
Key Financial Metrics
The filing provides Consumer Healthcare turnover data in GBP millions (£m) for various periods in 2019 and 2018, distinguishing between "Reported" and "Pro-forma" growth rates (Constant Exchange Rate). The filing does not provide consolidated group revenue, profit, cash flow, margins, debt, or liquidity metrics; it focuses exclusively on segment sales.
| Category | 2019 Full Year Turnover (£m) | 2019 Full Year Reported Growth (%) | 2019 Full Year Pro-forma CER Growth (%) |
|---|---|---|---|
| Oral health | 2,673 | 7 | 7 |
| Pain relief | 1,781 | 24 | 4 |
| Respiratory health | 1,186 | 9 | (2) |
| Vitamins, minerals and supplements | 611 | >100 | (3) |
| Digestive health and other | 1,646 | 15 | - |
| Total Consumer Healthcare | 7,897 | 20 | 3 |
| Brands divested and under review | 1,098 | - | (4) |
| Grand Total | 8,995 | 17 | 2 |
Material Changes Versus Prior Period
- Reporting Structure: The primary change is the reclassification of sales. "Nutrition" and "Skin health" categories are discontinued. Sales are now reported under Oral health, Pain relief, Respiratory health, Vitamins/minerals/supplements, and Digestive health/other.
- Portfolio Focus: The new categories reflect a focus on core categories via targeted divestments. For example, the "Vitamins, minerals and supplements" category shows reported growth of over 100% in 2019, driven by the inclusion of brands previously in the Nutrition category and the Pfizer acquisition.
- Pro-forma Adjustments: Reported growth figures for 2019 are significantly higher than pro-forma growth figures (e.g., Pain relief reported at 24% vs. pro-forma 4%) because the reported figures include the full impact of the Pfizer acquisition in the current period, whereas pro-forma figures adjust the prior year to include Pfizer's results for a like-for-like comparison.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance, profit outlook, or specific risk factors beyond the standard cautionary statement regarding pro-forma growth rates. Management commentary emphasizes that the revised disclosure provides greater transparency into the drivers of the Consumer Healthcare Joint Venture's performance. The pro-forma growth rates are explicitly stated as illustrative only and do not represent actual historical results or future performance, nor do they reflect anticipated synergies.
Investor Verification Checklist
- Verify the specific brand allocations within the new "Digestive health and other" and "Vitamins, minerals and supplements" categories to understand the composition of the >100% reported growth in vitamins.
- Confirm the impact of the Pfizer acquisition on the "Pro-forma" growth rates versus the "Reported" rates to assess organic performance.
- Review the list of "Brands divested and under review" to understand the scale of the portfolio reduction (e.g., Horlicks sale to Hindustan Unilever).
- Check subsequent Q1 2020 earnings releases to see the first application of this new reporting format for the current period.